Navigation Links
PhysIQ Personalized Physiology Analytics (PPA) Wins DPharm Idol 2017
Date:9/12/2017

PhysIQ, a Chicago-based company that provides a Personalized Physiology Analytics (PPA) and highly scalable cloud-based platform for ambulatory patient monitoring and clinical trial support, earned DPharm Idol 2017 honors at the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials conference in Boston.

Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The company provides an FDA 510k-cleared data analytics platform that processes an individual's vital signs from wearable sensors to create a personalized dynamic baseline.

"Winning DPharm Idol 2017 is a fantastic development in what has been an enormously successful year for PhysIQ," said Chris Economos, Vice President of Business Development for PhysIQ. "Pharma and biotech companies are now realizing the transformational potential of continuous biosensor data, and PhysIQ is proud to be working with the biggest names in the industry to collect and analyze these data sets using its FDA-cleared machine learning analytics. We are grateful to the DPharm leadership for bringing together such an impressive event to showcase the exciting innovation happening in real-world data collection and clinical trials overall."

"PhysIQ offers a solution which has multiple applications," DPharm Idol judge Laura Galuchie said. "We liked their ability to establish a unique 'normal' for each patient by analyzing data from commercially available biosensors. Having real-time alerts for clinicians, both in and out of clinical trials, is a game-changer."

The DPharm Idol competition enables participating companies to showcase their disruptive clinical trial services or technologies. The following companies participated in this year's DPharm Idol:

  •     PhysIQ
  •     Outcome Health
  •     Deep 6 AI
  •     eClinical Solutions
  •     VitalTrax
  •     Prevail InfoWorks

"Out of the six startup companies that presented this year with transformative technologies, we applaud PhysIQ, which was selected based on their potential to bring personalized insights based on continuous patient monitoring," DPharm Idol judge Chandra Ramanathan added.

DPharm Idol contestants were evaluated by a panel of clinical trial experts. This year's DPharm Idol judges were:

  •     Esther Dyson, Executive Founder, Way to Wellville
  •     Laura Galuchie, TransCelerate Program Lead, Merck
  •     Christian Gossens, PhD, MBA, Global Head Early Development Workflows, pRED Informatics, Roche Pharmaceutical Research and Early Development (pRED)
  •     Hassan Kadhim, Business Consultant, IS BP R&DM, Boehringer Ingelheim
  •     Andreas Koester, MD, PhD, Vice President, Innovation, R&D Operations, Janssen
  •     Sarah Krüg, Executive Director/President, Cancer 101/Society of Participatory Medicine
  •     Jacob LaPorte, PhD, Head of Digital Development, Novartis
  •     Ülo Palm, MD, PhD, Senior Vice President, Drug Development Operations, Allergan
  •     Chandra Ramanathan, PhD, MBA, Head, East Coast Innovation Center, Bayer, US
  •     Jane Rhodes, PhD, Senior Director, New Initiatives, Biogen Idec
  •     Dan Rothman, Chief Information Officer, Roivant Sciences
  •     Alicia Staley, Patient Advocate

DPharm is the annual conference that promotes clinical trial disruption and innovation. DPharm hosts hundreds of R&D innovators who participate in educational sessions, interactive presentations and networking events designed to raise the bar for the next generation of clinical trials. DPharm is organized by the Conference Forum.

About The Conference Forum

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. To find out more, please visit their website.

About PhysIQ

PhysIQ is a company dedicated to enabling proactive care delivery models through its Personalized Physiology Analytics (PPA) and highly scalable cloud-based platform. The PhysIQ FDA 510k-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, PhysIQ's analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health and warrant clinical attention. With applications in both healthcare delivery and clinical trial support, PhysIQ is transforming continuous physiological data into insight for providers, health systems, payers and pharmaceutical and medical device companies. For more information, please visit the PhysIQ website.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14686842.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Director of Scientific Programs of NIH’s All of Us Research Program to Provide Update at the 9th Annual Personalized & Precision Medicine Conference
2. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
3. ISABS: Personalized Medicine Conference With Nobel Prize Laureates Participation to be Held in Dubrovnik, Croatia
4. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
5. Proove Health Foundation Is Created to Support the Role of Personalized Medicine in Public Health Epidemics
6. IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
7. Proove Biosciences Highlights Personalized Medicine Technology as an Approach to Reduce Prescription Drug Abuse
8. Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference
9. Global Scientific and Commercial Aspects of the Personalized Medicine Market 2015 - Estimates to 2024
10. New Genomic Insights May Lead to More Personalized Approaches to Treatment of Pediatric Blood Diseases
11. BC Platforms Launches Personalized Precision Medicine Initiative With the University of Colorado Anschutz Medical Campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... ... of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that ... human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically ...
(Date:9/14/2017)... , ... September 14, 2017 , ... One of the ... Saturday, Sept. 16. , For six hours that day, the GenCure Marrow Donor Program ... more than 30 H-E-B grocery stores in San Antonio. , The registration tables will ...
(Date:9/13/2017)... ... September 13, 2017 , ... AMRI, a global contract ... patient outcomes and quality of life for more than 25 years, today announced ... expert to the International Standards Organization/Technical Committee 194: Biological and Clinical Evaluation ...
(Date:9/12/2017)... ... September 12, 2017 , ... Avomeen.com, the analytical ... and development companies will be exhibiting at the 16th annual Contract Pharma Conference ... Pharma is an educational conference for pharma and bio-pharma professionals that has ...
Breaking Biology Technology:
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):